Groveman BR, Orru CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol Commun. 2018;6(1):7.

Article  PubMed  PubMed Central  Google Scholar 

McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–55.

Article  PubMed  PubMed Central  Google Scholar 

Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disorders: Official J Mov Disorder Soc. 2012;27(3):349–56.

Article  Google Scholar 

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.

Article  PubMed  PubMed Central  Google Scholar 

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disorders: Official J Mov Disorder Soc. 2007;22(12):1689–707. quiz 837.

Article  Google Scholar 

Ferreira D, Przybelski SA, Lesnick TG, Lemstra AW, Londos E, Blanc F, et al. beta-amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology. 2020;95(24):e3257–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toledo JB, Abdelnour C, Weil RS, Ferreira D, Rodriguez-Porcel F, Pilotto A, et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimer’s Dement J Alzheimer’s Assoc. 2023;19(1):318–32.

Article  Google Scholar 

Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov Disorders: Official J Mov Disorder Soc. 2016;31(8):1203–8.

Article  CAS  Google Scholar 

Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, et al. Pathological alpha-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol. 2016;131(3):393–409.

Article  CAS  PubMed  Google Scholar 

Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, van Gerpen JA, et al. The limbic and neocortical contribution of alpha-synuclein, tau, and amyloid beta to disease duration in dementia with Lewy bodies. Alzheimer’s Dement J Alzheimer’s Assoc. 2018;14(3):330–9.

Article  Google Scholar 

Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013;1(1):65.

Article  PubMed  PubMed Central  Google Scholar 

Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2020;94(20):e2076–87.

Article  PubMed  PubMed Central  Google Scholar 

Ryman SG, Yutsis M, Tian L, Henderson VW, Montine TJ, Salmon DP, et al. Cognition at each stage of Lewy body disease with co-occurring Alzheimer’s disease pathology. J Alzheimer’s Disease: JAD. 2021;80(3):1243–56.

Article  CAS  PubMed  Google Scholar 

Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, et al. The Alzheimer’s disease centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23(2):91–101.

Article  PubMed  PubMed Central  Google Scholar 

Besser LM, Kukull WA, Teylan MA, Bigio EH, Cairns NJ, Kofler JK, et al. The revised National Alzheimer’s Coordinating Center’s neuropathology form-available data and new analyses. J Neuropathol Exp Neurol. 2018;77(8):717–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1–11.

Article  CAS  PubMed  Google Scholar 

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.

Article  CAS  PubMed  Google Scholar 

Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3 of the Alzheimer disease centers’ neuropsychological test battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018;32(1):10–7.

Article  PubMed  PubMed Central  Google Scholar 

Mukherjee S, Choi SE, Lee ML, Scollard P, Trittschuh EH, Mez J, et al. Cognitive domain harmonization and cocalibration in studies of older adults. Neuropsychology. 2023;37(4):409–23.

Article  PubMed  Google Scholar 

Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013;74(3):478–89.

Article  PubMed  Google Scholar 

Friedman HF. Multivariate adaptive regression splines. Annals Stat. 1991;19(1):1–67.

Google Scholar 

Kuhn M. Building predictive models in R using the caret. J Stat Softw. 2008;28(5).

Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, et al. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2020;91(1):109–10.

Article  PubMed  Google Scholar 

Ferman TJ, Aoki N, Boeve BF, Aakre JA, Kantarci K, Graff-Radford J, et al. Subtypes of dementia with Lewy bodies are associated with alpha-synuclein and tau distribution. Neurology. 2020;95(2):e155–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disorders: Official J Mov Disorder Soc. 2012;27(8):965–73.

Article  Google Scholar 

Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG, et al. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58–67.

Article  CAS  PubMed  Google Scholar 

Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre. Brain. 2013;136(Pt 9):2697–706.

Article  PubMed  PubMed Central  Google Scholar 

Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, et al. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114–24.

Article  CAS  PubMed  Google Scholar 

Palmqvist S, Rossi M, Hall S, Quadalti C, Mattsson-Carlgren N, Dellavalle S et al. Cognitive effects of lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29(8):1971–8.

Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S et al. Clinical effects of lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964–70.

Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, Toledo JB, Ferreira D, Urwyler P, et al. Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener. 2022;11(1):24.

Article  PubMed  PubMed Central  Google Scholar 

Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157–69.

Article  PubMed  Google Scholar 

Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2010;257(3):359–66.

Article  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA: J Am Med Association. 2023;330(6):512–27.

van de